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Purpose: Tenofovir disoproxil is an antiretroviral agent belonging to the class of nucleoside reverse-
transcriptase inhibitors (NRTI’s) used in the management of HIV infection in adults. This study is aimed 
at developing and validating four simple, sensitive and cost-effective analytical methods for ascertaining 
the drug’s quality.  
Methods: Tenofovir disoproxil forms a complex of 1:1 molar ratio with fumaric acid that was employed 
in its aqueous titration with sodium hydroxide. Non-aqueous titration was also employed for its 
determination. Extractive ion-pair spectrophotometric technique using methyl orange was similarly 
employed to evaluate quantitatively the amount of tenofovir in the formulation. The drug was further 
assayed by forming a charge-transfer complex with chloranilic acid and the coloured complex assayed 
spectrophotometrically.  
Results: Recovery experiments carried out by the proposed methods showed that aqueous titration 
gave mean recovery of 97.7 % while non-aqueous titration gave 97.5 % recovery. The technique of 
extractive ion-pair spectrophotometry similarly gave 98.7 % mean recovery while charge transfer 
spectrophotometry gave 99.6 % for the same parameter.  
Conclusion: These results show that the proposed methods are accurate, precise and sensitive. In 
addition to being simple and cost-effective, they can conveniently be used for the assay of tenofovir 
which has yet no official assay procedure. This investigation, therefore, contributes to the knowledge on 
the development of assay techniques for a drug that is already extensively distributed in the market. 
 
Keywords: Tenofovir disoproxil fumarate, Extractive spectrophotmetry, Charge-transfer  complexation, 
Titrimetric analysis.  
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INTRODUCTION 
 
The number of people living with HIV/AIDS 
(PLWHA) is close to 40 million, according to 
UNAIDS report for 2006. Despite intensive 
campaigns and advocacy activities, the 
spread of HIV/AIDS does not seem to abate 
as over 4 million peoples are reported to be 
infected annually [1]. The majority of these 
victims are found in sub-Saharan Africa and 
South East Asia, thus placing an intolerable 
burden on the weak economies of these 
countries. 
 
In the last decade and half, a number of anti-
retroviral drugs have been developed as 
chemotherapeutic agents and are broadly 
classified as nucleoside reverse-transcriptase 
inhibitors (NRTIs), non-nucleoside reverse-
transcriptase inhibitors (NNRTIs) and 
protease inhibitors (PIs). NRTIs constitute the 
backbone of HIV/AIDS treatment and they 
likely will continue to dominate the market for 
some time to come. The mechanism of action 
of NRTIs is that the drug becomes 
incorporated into the ‘primer’ strand during 
viral DNA synthesis, thus terminating the 
nucleotide synthesis prematurely [2]. 
 
Tenofovir disoproxil fumarate is one of the 
latest NRTI to be approved for the treatment 
of HIV/AIDS in the USA. Its chemical name is 
9-[(R)-2[[bis[[(isopropoxycarbonyl)oxy]-
Methoxy]phosphinyl]methoxy]propyl]adenine 
fumarate. Tenofovir disoproxil fumarate is, 
therefore, an acyclic nucleoside phosphonate 
diester analogue of adenosine 
monophosphate. The ester is first hydrolyzed 
followed by phosphorylation by cellular 
enzymes de novo to form tenofovir 
diphosphate. This drug now competes with 
the natural substrate, deoxyadenosine 5
1
-  
triphosphate, for incorporation into the viral 
DNA. Tenofovir, in combination with 
emtricitabine (Atripla), was recently 
introduced into the market as a combined 
formulation (Truvada
®
) to overcome reported 
cases of therapeutic failures. Tenofovir, in 
particular, has been shown to be active 
against all sub-types of HIV-1 and has even 
been shown to be specific against HIV-2 with 
half maximal effective concentration (EC50) 
values that range from 1.6 to 4.9 µM [3]. 
 
Pharmacokinetic studies on tenofovir 
formulation have shown its oral bioavailability 
to be improved following administration with a 
high fat diet with parameters such as area 
under the curve (AUC) and maximum 
concentration (Cmax) increasing by 14 and 40 
%, respectively [3]. Creatine phosphokinase 
enzyme levels have been reported to 
increase when tenofovir is administered to 
HIV patients [4]. Similar increases have also 
been reported for aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) in 
patients receiving tenofovir [5]. The 
pharmacology of tenofovir has been well 
documented in the literature [6].  
 
Since tenofovir was recently introduced into 
the market, analytical procedures for its 
quality assurance have not appeared in 
international monographs. However, reports 
have appeared in which the drug was 
determined in human plasma using reverse-
phase liquid chromatography (HPLC) 
employing UV detector to establish its 
absorption profile [3,7]. The system was able 
to identify tenofovir to a level of 10 ng/ml [7]. 
Characterization of NRTIs and NNRTIs has 
been advocated using Raman spectra 
analysis [8].  
 
Chemical analysis of tenofovir, taking 
advantage of the functional groups and their 
reactivity, have not appeared in the literature 
to any significant extent. In fact, to the best of 
our knowledge, pharmacopoeias have no 
analytical procedures for anti-retroviral drugs 
generally. Therefore, there is a need to 
develop evaluative techniques that ensure 
the quality of these drugs entering the 
market. The demand for antiretrovirals 
(ARVs) is so high that the likelihood of entry 
of sub-standard and even fake ARVs into the 
market cannot be discountenanced. 
Therefore, this study is aimed at developing 
simple, sensitive and cost-effective methods 
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Tenofovir disoproxil fumarate tablets were 
kindly provided by Professor JA Idoko, 
Director of Aids Prevention in Nigeria [APIN] 
Clinic, University of Jos Teaching Hospital, 
Jos, Nigeria. The following reagents were 
obtained from May & Baker, England: sodium 
hydroxide pallets, sulphamic acid, 
phenolphthalein and bromothymol blue 
indicators, and acetone. Similarly, glycine, 
sodium chloride, hydrochloric acid, ethanol, 
chloroform and 1, 4-dioxan, all of AnalaR 
grade, were obtained from BDH, England. 
Chloranilic acid (Riedel de Haem, Germany) 
was recrystallized from acetone. All other 
reagents were of analytical grade and used 




(a) Aqueous titration: 
 
Twenty-two (22) tablets of tenofovir disoproxil 
fumarate (label claim: 300 mg) were finely 
powdered in a porcelain mortar and an 
amount equivalent to 6.355 g of tenofovir 
disoproxil fumarate was suspended in 100 
mL of water to give a solution with a strength 
of 0.1M. This was followed by filtration 
through Whatman filter paper no. 1 to remove 
the excipients. Sodium hydroxide solution 
(0.2M) was similarly prepared and 
standardized with sulphamic acid. The base 
was titrated against fumaric acid in the 
formulation using phenolphthalein indicator 
with a pink colour change obtained at the 
titration end-point. Titration values were 
generated severally until consistent titre 
values (5 replicate readings) were obtained.  
 
(b) Non-aqueous titration: 
 
Tenofovir disoproxil fumarate tablets, 
neutralized by titration with sodium hydroxide 
as described in above (a), was extracted with 
chloroform (25 mL x 4) and evaporated to 
dryness. The dry tenofovir disoproxil residue 
was reconstituted in glacial acetic acid and 
subjected to non-aqueous titrations by the 
method described in British Pharmacopoeia 
[9]. Five replicate determinations were carried 
out. 
 
Extractive spectrophotometric procedure 
 
(a) Preparation of buffer (pH 1.5) 
 
7.5 g of glycine and 5.85 g of sodium chloride 
were dissolved in 100 mL distilled water. A 
portion of this solution, 60 mL, was mixed 
with 140 mL of 0.1M hydrochloric acid and 
the pH adjusted to 1.5. 
 
(b) Preparation of stock solution 
 
The pure drug (100 mg) was dissolved in 100 
mL of 5M hydrochloric acid in a volumetric 
flask to form the stock solution. Aliquots of 
the stock solution were similarly diluted to 
obtain working concentrations in the range of 
10 to 100 µg/mL. 
 
(c) Extractive ion-pair pectrophotometry  
 
From the working solutions (10 to 100 
µg/mL), 5 mL was placed in a series of 50 mL 
separating funnels; 5 mL of glycine buffer (pH 
1.5) was added followed by 4 mL indicator 
(thymol blue, 0.4mg/ml) and 20 mL of 
chloroform. The separating funnels were 
stoppered, vigorously shaken for 5 min and 
allowed to stand. The chloroform layer was 
filtered through a cotton plug and the 
extraction procedure was repeated severally 
(25 ml x 4) in order to completely extract the 
drug-thymol complex into the chloroform 
layer. The absorbance was then read with a 
Jenway spectrophotometer (model 6405, 
England). These determinations were made 
in quintuplicate for each concentration of the 
drug. The blank solution was prepared in a 
similar way but without the drug. The 
absorption maximum for complexation was 
determined and the Beer-Lambert plot 
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generated using the different working 
concentrations previously prepared. The plot 
of absorption against concentration was 
obtained from the mean of five replicate 
determinations. The curve was validated by 
methods previously reported [10]. Molar 
absorptivities, regression equations and 
standard deviations were similarly 
determined. The analytical technique was 
optimized by a method reported earlier [10]. 
 
Formation of charge-transfer complexes 
and spectral properties 
 
Chloranilic acid (2.5 x 10
-4
M) was prepared in 
1, 4-dioxan and its absorption maximum 
determined spectrophotometrically (Jenway, 
Model 6405, England). Solutions of tenofovir 
disoproxil freed from the fumarate (see 
section on non-aqueous titration)  (3.0 x 10
-
2
M) was similarly prepared in 1, 4-dioxan. 
Equal volumes of the drug and chloranilic 
acid were quantitatively transferred into 10 
mL volumetric flasks. The volumes were 
brought up to mark and allowed to stand for 
15 min to allow full colour development. It 
was observed that a purple complex was 
formed immediately after mixing. The 
solutions were again scanned 
spectrophotometrically and the absorption 
maximum deduced from the mean of five (5) 
different measurements. Stoichiometric 
relationship between chloranilic acid and 
tenofovir was established by the method 
previously described [11].  
 
Construction of calibration curve and its 
validation 
 
A stock solution of tenofovir disoproxil (3.5 x 
10
-2
M) was prepared, 1 – 5 mL of which was 
transferred to separate volumetric flasks and 
1 mL of chloranilic acid added. Quadruplicate 
preparations were made for each volume 
taken. The flasks were thoroughly shaken 
and allowed to stand for at least 20 min 
before their absorbances were read 
spectrophotometrically. The means of the 
absorbances were plotted against 
concentration and the regression parameters 
determined. Validation of the plot was carried 
out essentially by the same method as above 
except that different concentrations of the 
drug, were prepared and their absorbances 
read spectrophotometrically. These absor-
bances were then converted to the 
corresponding concentrations using the 
calibrated curve. 
 
Determination of actual content of 
tenofovir by extractive and charge-
transfer techniques 
 
Four different batches of tenofovir disoproxil 
were investigated and the following 
procedure was carried out in quadruplicate. 
Having constructed the calibration curves for 
both ion-pair extractive and charge-transfer 
complexes as described above, different 
concentrations of tenofovir disoproxil were 
taken, treated according to the procedures 
described above, and their absorbances 
determined. Recovery (%) was determined 
by comparing the concentrations obtained 
from the validated curves with the actual 
concentrations of the drugs taken. Relative 




The results, expressed as mean ± standard 
deviation, were calculated using Microsoft 




The results for the recovery experiments for 
both the aqueous and non-aqueous titration 
are shown in Table 1 while those for the 
extractive ion-pair and charge-transfer 
spectrophotometry are listed in Table 2. 
Figure 1 shows the determination of 
absorbance maximum for the tenofovir-
thymol blue complex while Figure 2 indicates 
the absorbance maxima for chloranilic acid 
and the complex. The wavelength of 
maximum absorption for the tenofovir-thymol 
blue complex was 405 nm while that for the 
tenofovir-chloranilic acid complex was 550 
nm. Therefore, subsequent measurements 
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were carried out at these respective 
wavelengths.  
 
Table 1:  Recovery data for aqueous and 
























97.5 ± 0.4 
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Fig 1: Determination of absorbance maxi-
















































Fig  2: Determination of absorbance 
maxima for chloranilic acid (▲) and 




Tenofovir disoproxil is formulated as a 1:1 
molar complex with sodium fumarate; 
therefore, the quantitative determination of 
the fumarate constitutes an indirect but 
accurate technique for the determination of 
tenofovir disoproxil. Fumaric acid, being a 
dicarboxylic acid, is sufficiently soluble in 
water, and therefore, its titration with a base 
provides an accurate method using 
phenolphthalein as indicator. In this 
investigation, percent recovery from aqueous 
titrations of the compound was 97.7 ± 0.6 
(Table 1).  
 
In the non-aqueous titration method, the 
percent recovered from the experiment was 
97.5 ± 0.4.  
 
These different values show that either 
method is suitable for the quantitative 
analysis of tenofovir disoproxil fumarate.  
 
Extractive ion-pair spectrophotometry 
 
The complex formed between tenofovir 
disoproxil and thymol blue absorbed 
maximally (λmax) at 405 nm (Fig 1). The light 
yellow colour of the complex was stable for 
12 h. The limit of detection and quantitation 
were 0.01 to 0.02 µg /mL and 0.04 to 0.10 µg 
/mL, respectively. The plot of concentration 
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versus absorbance of the drug ( 0.01 to 0.10 
mg/mL)  produced a linear plot. When the 
calibrated and validated curves were 
subjected to linear regression analysis, the 
equation obtained (Eq 1) satisfied all linearity 
requirements for the various concentrations 
investigated, with a regression coefficient of 
0.9995.  
 
Yabs = 22.2 x – 0.0067 ……………….…… (1) 
 
where Yabs  is absorbance and x is the drug 
concentration. The plot obeyed Beer 
Lambert’s law. The standard deviations of the 
slope and intercept were 1.05 and 0.001, 
respectively. The molar extinction coefficient 
and Sandells’ sensitivity were calculated to 
be 10390.4 mol. L
-1
 and 200, respectively. 
The recovery value for the extractive ion-pair 




Chloranilic acid in 1,4-dioxan is light yellow in 
colour and absorbs maximally at 420 nm. In 
the presence of tenofovir disoproxil, the 
colour of the complex formed spontaneously 
changed to purple with an absorption 
maximum of 550 nm (Fig 2). The purple-
coloured solution was stable beyond 10 h. 
The solvent, 1,4-dioxan, is inert, and it seems 
that the analyte was stable throughout the 
duration of experiment.  
 
The limit of detection (LOD) and limit of 
quantitation (LOQ) were 1 µg / mL and 5 
µg/mL, respectively. The plots of drug 
concentration versus absorbance were linear 
between 1 and 10 µg/mL. Optimization of the 
various concentrations during the 
experiments with no significant differences in 
standard deviations (p ≥ 0.01) suggests that 
the method produced consistent results. 
Several replicate determinations were carried 
out from which regression equations, 
regression coefficients, standard deviations in 
slope and intercept were calculated. The 
regression equation obtained, with a 
regression coefficient of 0.9989, is shown in 
Eq 2. 
 
Aabs  =   22.2x – 0.0067 …… ………..…… (2)  
 
where Aabs = absorbance of analyte, x = 
concentration of analyte in the final mixture in 
moles. The relative standard deviations of the 
slope and intercept were calculated to be 
2.30 and 0.75 %, respectively. Molar 
absorbtivity and Sandell’s sensitivity were 

















Fumaric acid, a dicarboxylic acid, is a very 
strong acid and therefore qualifies to be 
titrated with a strong base like sodium 
hydroxide, the end-point of which can be 
achieved with an indicator such as 
phenolphthalein. Although, other aqueous 
indicators such as methyl orange can be 
used, phenolphthalein gives a sharper end-
point, hence its choice in this study. The 
recovery of 97.7 ± 0.6 % attests to the 
accuracy of this method. In non-aqueous 
titration, the limit of accuracy is usually 
governed by the suitability of the indicator 
and the skill displayed during measurement. 
Even in determining the end-point 
potentiometrically, skillful measurement is a 
requirement for accurate result. The result 
obtained in this study shows that the 
technique is accurate and reproducible.  
 
Extractive ion-pair method 
 
In the extractive ion-pair method, the 
observation of a yellow colour in the 
chloroform layer suggests that a complex 
was formed between tenofovir and thymol 
blue since thymol blue alone was insoluble in 
chloroform at the pH used. Thus, the yellow 
colour was due to a complex formed between 
the positively charged tenofovir disoproxil in 
the acidic buffer and the negatively charged 
thymol blue in the same medium. It would 
appear from Job’s continuous variation plot 
obtained by a method described previously 
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[11] that the stoichiometric relationship 
between the drug and thymol blue was 1:1. 
This observation is supported by the fact that 
the complex obeyed Beer-Lambert’s Law. 
  
In ion-pair complexation, it’s common to find 
isomeric and termolecular structures. Where 
the complexation exceeds the 1:1 ratio, Beer-
Lambert’s Law would not be obeyed. In this 
study, Beer-Lambert’s Law was obeyed, 
suggesting that isomeric structures were not 
formed. These data confirm that the various 
batches assayed met pharmaceutical 
standards for therapeutic use [9]. The low 
values of the standard deviations also 
demonstrate the accuracy of the technique. 
Comparison of this technique with aqueous 
and non-aqueous titrations did not reveal any 
statistically significant difference (p < 0.05). In 
our view, therefore, extractive ion-pair 
spectrophotometry can be used as a tool in 
the quality assurance of tenofovir disoproxil 
and the method is particularly attractive since 




The spontaneous purple colour formed 
between chloranilic acid and tenofovir 
represent a bathochromic shift with respect to 
chloranilic acid. Tenofovir is a powerful 
electron donor due to the presence of an 
amino group; therefore, the purple colour is 
due to donor-acceptor interaction.  The 
stoichiometric ratio of 1:1 observed in this 
study is consistent with earlier reports in the 
literature [10,12,13]. 1,4-Dioxan was chosen 
for this analysis because of its low dielectric 
constant and its reduced capacity to solvate 
the drug molecules, thus optimizing the 
opportunity for charge transfer to take place. 
The concentration ratio of donor to acceptor 
in these studies is usually 1:10 as a result of 
the equilibrium conditions necessary to 
satisfy the theoretical framework of Benesi-
Hildebrand equation [14]. Published reports 
[15,16] on the nature of charge-transfer 
interactions support the conclusion that 
colour change is the evidence for the 
existence of the complex. A previous attempt 
to establish electronic shifts by infra-red 
spectrophotmetry was unsuccessful [17]. 
 
Comparison of the four methods used in this 
work for the analysis of tenofovir disoproxil 
fumarate did not show any difference in their 
levels of accuracy and reproducibility of 
techniques. The relatively lower value 
obtained for the non-aqueous titration method 
has more to do with the detection of the end-




Tenofovir disoproxil fumarate is 
manufactured by only one company under 
the brand name, Viread
®
. We therefore 
conducted quantitative assay on this one 
brand. The methods proposed in this study 
have been demonstrated to be simple, 
sensitive and reproducible and are thus 
suitable for the determination of tenofovir 
disoproxil fumarate alone and also in a tablet 
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